These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34605709)

  • 41. Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma.
    Mathai AM; Kapadia MJ; Alexander J; Kernochan LE; Swanson PE; Yeh MM
    Am J Surg Pathol; 2012 Jul; 36(7):980-6. PubMed ID: 22446942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
    Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
    Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
    Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
    Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
    Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
    Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
    Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
    Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preablation neutrophil-to-lymphocyte ratio as an independent prognostic factor in locally advanced hepatocellular carcinoma patients following radiofrequency ablation.
    Tan W; Sun W; Li X; Zhao L; Wang C; Zang A; Kong X
    J Cancer Res Ther; 2018 Jan; 14(1):84-89. PubMed ID: 29516965
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.
    Yasuoka H; Asai A; Ohama H; Tsuchimoto Y; Fukunishi S; Higuchi K
    Sci Rep; 2020 Jun; 10(1):10377. PubMed ID: 32587357
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3.
    Miller TJ; McCoy MJ; Hemmings C; Bulsara MK; Iacopetta B; Platell CF
    Pathology; 2017 Dec; 49(7):721-730. PubMed ID: 29102042
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
    Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
    Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
    Semaan A; Dietrich D; Bergheim D; Dietrich J; Kalff JC; Branchi V; Matthaei H; Kristiansen G; Fischer HP; Goltz D
    Virchows Arch; 2017 Feb; 470(2):185-196. PubMed ID: 27913861
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
    Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
    J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology.
    Kan G; Dong W
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3063-71. PubMed ID: 26367730
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?
    Sun DW; An L; Huang HY; Sun XD; Lv GY
    Clin Transl Oncol; 2021 Jan; 23(1):82-91. PubMed ID: 32462395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased frequency of Foxp3+ regulatory T cells in mice with hepatocellular carcinoma.
    Du Y; Chen X; Huang ZM; Ye XH; Niu Q
    Asian Pac J Cancer Prev; 2012; 13(8):3815-9. PubMed ID: 23098476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of a FOXP3(+)CD3(+)CD56(+) population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma.
    Li X; Peng J; Pang Y; Yu S; Yu X; Chen P; Wang W; Han W; Zhang J; Yin Y; Zhang Y
    Sci Rep; 2015 Oct; 5():14757. PubMed ID: 26437631
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Prognostic Role of a Combined Fibrinogen and Neutrophil-to-Lymphocyte Ratio Score in Patients with Resectable Hepatocellular Carcinoma: A Retrospective Study.
    Kong W; Xu H; Cheng J; Fang Z; Wang H; Zhang J; Wang X; Dai T; Gao Y
    Med Sci Monit; 2020 Jan; 26():e918824. PubMed ID: 31929496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma.
    Li X; Chen ZH; Ma XK; Chen J; Wu DH; Lin Q; Dong M; Wei L; Wang TT; Ruan DY; Lin ZX; Xing YF; Deng Y; Wu XY; Wen JY
    Tumour Biol; 2014 Nov; 35(11):11057-63. PubMed ID: 25095975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.